Page last updated: 2024-10-29

staurosporine aglycone and Parkinsonian Disorders

staurosporine aglycone has been researched along with Parkinsonian Disorders in 1 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"Sitagliptin rescued the memory deficits, which was achieved by upregulating BDNF to prevent neuronal death and dendritic spine loss."1.48Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss. ( Li, C; Li, J; Li, M; Ma, L; Zhang, S, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, J1
Zhang, S1
Li, C1
Li, M1
Ma, L1

Other Studies

1 other study available for staurosporine aglycone and Parkinsonian Disorders

ArticleYear
Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss.
    Neurological research, 2018, Volume: 40, Issue:9

    Topics: Animals; Antiparkinson Agents; Avoidance Learning; Brain-Derived Neurotrophic Factor; Carbazoles; En

2018